JP6997095B2 - 抗菌性化合物およびその使用 - Google Patents

抗菌性化合物およびその使用 Download PDF

Info

Publication number
JP6997095B2
JP6997095B2 JP2018546705A JP2018546705A JP6997095B2 JP 6997095 B2 JP6997095 B2 JP 6997095B2 JP 2018546705 A JP2018546705 A JP 2018546705A JP 2018546705 A JP2018546705 A JP 2018546705A JP 6997095 B2 JP6997095 B2 JP 6997095B2
Authority
JP
Japan
Prior art keywords
mmol
dimethylamino
methoxyquinoline
bromo
etoac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018546705A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019507769A (ja
Inventor
アンナ マリー アプトン，
クリストファー ブレア クーパー，
コーエンラード ジョゼフ ロードヴェイク マルセル アンドリース，
ジェローム エミール ジョルジュ ギーユモン，
デン ブルーク， ヴァルター マルセル マティルデ ファン
ブライアン デスモンド パーマー，
ジェンクン マ，
Original Assignee
ザ グローバル アライアンス フォー ティービー ドラッグ デベロップメント， インコーポレイテッド
ヤンセン ファーマシューティカ ナムローゼ フェンノートシャップ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ グローバル アライアンス フォー ティービー ドラッグ デベロップメント， インコーポレイテッド, ヤンセン ファーマシューティカ ナムローゼ フェンノートシャップ filed Critical ザ グローバル アライアンス フォー ティービー ドラッグ デベロップメント， インコーポレイテッド
Publication of JP2019507769A publication Critical patent/JP2019507769A/ja
Priority to JP2021138560A priority Critical patent/JP7453946B2/ja
Application granted granted Critical
Publication of JP6997095B2 publication Critical patent/JP6997095B2/ja
Priority to JP2023204901A priority patent/JP2024028841A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2018546705A 2016-03-07 2017-03-07 抗菌性化合物およびその使用 Active JP6997095B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021138560A JP7453946B2 (ja) 2016-03-07 2021-08-27 抗菌性化合物およびその使用
JP2023204901A JP2024028841A (ja) 2016-03-07 2023-12-04 抗菌性化合物およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662304661P 2016-03-07 2016-03-07
US62/304,661 2016-03-07
PCT/US2017/021031 WO2017155909A1 (fr) 2016-03-07 2017-03-07 Composés antibactériens et utilisations de ceux-ci

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021138560A Division JP7453946B2 (ja) 2016-03-07 2021-08-27 抗菌性化合物およびその使用

Publications (2)

Publication Number Publication Date
JP2019507769A JP2019507769A (ja) 2019-03-22
JP6997095B2 true JP6997095B2 (ja) 2022-02-03

Family

ID=59790723

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018546705A Active JP6997095B2 (ja) 2016-03-07 2017-03-07 抗菌性化合物およびその使用
JP2021138560A Active JP7453946B2 (ja) 2016-03-07 2021-08-27 抗菌性化合物およびその使用
JP2023204901A Pending JP2024028841A (ja) 2016-03-07 2023-12-04 抗菌性化合物およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021138560A Active JP7453946B2 (ja) 2016-03-07 2021-08-27 抗菌性化合物およびその使用
JP2023204901A Pending JP2024028841A (ja) 2016-03-07 2023-12-04 抗菌性化合物およびその使用

Country Status (12)

Country Link
US (2) US10508097B2 (fr)
EP (2) EP4148053A1 (fr)
JP (3) JP6997095B2 (fr)
KR (2) KR102480410B1 (fr)
CN (1) CN109069514B (fr)
AU (2) AU2017229128B2 (fr)
BR (3) BR122023025283A2 (fr)
CA (2) CA3226824A1 (fr)
EA (1) EA201891644A1 (fr)
ES (1) ES2934785T3 (fr)
WO (1) WO2017155909A1 (fr)
ZA (1) ZA201805523B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069514B (zh) * 2016-03-07 2023-12-29 结核病药物开发全球联盟公司 抗菌化合物及其用途
CN108929310A (zh) * 2018-06-29 2018-12-04 湖南华腾制药有限公司 一种二芳基喹啉衍生物的制备方法
CN108707138A (zh) * 2018-06-29 2018-10-26 湖南华腾制药有限公司 一种二芳基喹啉衍生物的制备方法
CN108689998A (zh) * 2018-06-29 2018-10-23 湖南华腾制药有限公司 一种二芳基喹啉衍生物的制备方法
CN108840857A (zh) * 2018-07-10 2018-11-20 湖南华腾制药有限公司 一种喹啉衍生物的制备方法
WO2020047596A1 (fr) * 2018-09-04 2020-03-12 Monash University Composés antibactériens et procédés d'utilisation
CN109535068B (zh) * 2018-12-26 2022-07-29 中国药科大学 吡啶取代查尔酮类化合物或其可药用的盐及其制备方法和用途
WO2021057190A1 (fr) * 2019-09-29 2021-04-01 上海阳帆医药科技有限公司 Composés quinoléine, leur procédé de préparation et utilisation associée

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006504658A (ja) 2002-07-25 2006-02-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キノリン誘導体およびミコバクテリア抑制剤としてのそれらの使用
JP2006182755A (ja) 2004-12-24 2006-07-13 Janssen Pharmaceut Nv 潜伏性結核の処置
JP2006342109A (ja) 2005-06-09 2006-12-21 Janssen Pharmaceut Nv 抗バクテリア剤としてのキノリン誘導体
JP2008500992A (ja) 2004-05-28 2008-01-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 薬剤耐性マイコバクテリア性疾患の処置のための置換キノリン誘導体の使用
JP2010511667A (ja) 2006-12-06 2010-04-15 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗菌性キノリン誘導体
JP2010511669A5 (fr) 2007-12-04 2010-11-18

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
SG162724A1 (en) * 2005-05-25 2010-07-29 Janssen Pharmaceutica Nv Process for preparing <alpha s, beta r>-6-bromo-alpha-[2-<dimethylamino>ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
JO2837B1 (en) * 2005-08-03 2014-09-15 جانسن فارمسيتكا ان في Quinoline derivatives acting as antibacterial agents
JO3271B1 (ar) 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
JO2970B1 (en) * 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
EP2195311B1 (fr) 2007-08-17 2011-03-23 Actelion Pharmaceuticals Ltd. Derives de la pyridine an tant que modulateurs du recepteur s1p1/edg1
WO2009083553A1 (fr) 2007-12-31 2009-07-09 Rheoscience A/S Composés azines en tant qu'activateurs de glucokinase
US20110059948A1 (en) * 2008-01-14 2011-03-10 Jyoti Chattopadhyaya Quinoline, naphthalene and conformationally constrained quinoline or naphthalene derivatives as anti-mycobacterial agents
UA103634C2 (en) 2008-09-26 2013-11-11 Берингер Ингельхайм Интернациональ Гмбх Azaindazole compounds as ccr1 receptor antagonists
JP5683489B2 (ja) 2009-01-12 2015-03-11 アレイ バイオファーマ、インコーポレイテッド ピペリジン含有化合物およびその用途
WO2010100475A1 (fr) 2009-03-02 2010-09-10 Astrazeneca Ab Dérivés de l'acide hydroxamique en tant qu'agents contre des bactéries à gram négatif
DK2841425T3 (en) * 2012-04-27 2016-06-27 Janssen Pharmaceutica Nv ANTIBACTERIAL QUINOLIN DERIVATIVES
US9572809B2 (en) * 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases
US9878982B2 (en) 2014-07-14 2018-01-30 Cisen Pharmaceutical Co., Ltd. Pyridine derivatives and anti-mycobacterial use thereof
CN109069514B (zh) * 2016-03-07 2023-12-29 结核病药物开发全球联盟公司 抗菌化合物及其用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006504658A (ja) 2002-07-25 2006-02-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キノリン誘導体およびミコバクテリア抑制剤としてのそれらの使用
JP2008500992A (ja) 2004-05-28 2008-01-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 薬剤耐性マイコバクテリア性疾患の処置のための置換キノリン誘導体の使用
JP2006182755A (ja) 2004-12-24 2006-07-13 Janssen Pharmaceut Nv 潜伏性結核の処置
JP2006342109A (ja) 2005-06-09 2006-12-21 Janssen Pharmaceut Nv 抗バクテリア剤としてのキノリン誘導体
JP2010511667A (ja) 2006-12-06 2010-04-15 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗菌性キノリン誘導体
JP2010511669A5 (fr) 2007-12-04 2010-11-18

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BALEMANS, W. et al.，Novel antibiotics targeting respiratory ATP synthesis in Gram-positive pathogenic bacteria，Antimicrobial Agents and Chemotherapy，2012年，Vol. 56，pp. 4131-4139
NATALIE, M. et al.，Screening for phospholipidosis induced by central nervous drugs: Comparing the predictivity of an in vitro assay to high throughput in silico assays，Toxicology in Vitro，2010年，Vol. 24，pp. 1417-1425

Also Published As

Publication number Publication date
CA3226824A1 (fr) 2017-09-14
CN109069514A (zh) 2018-12-21
JP7453946B2 (ja) 2024-03-21
ES2934785T3 (es) 2023-02-27
EP3426255B1 (fr) 2022-11-30
BR122021024097B1 (pt) 2024-04-30
WO2017155909A1 (fr) 2017-09-14
KR102480410B1 (ko) 2022-12-22
AU2017229128B2 (en) 2022-04-07
US10508097B2 (en) 2019-12-17
EP3426255A4 (fr) 2019-08-21
EA201891644A1 (ru) 2019-04-30
JP2021191769A (ja) 2021-12-16
CA3016068A1 (fr) 2017-09-14
AU2022204071A1 (en) 2022-06-30
AU2017229128A1 (en) 2018-09-06
KR20220016279A (ko) 2022-02-08
EP3426255A1 (fr) 2019-01-16
KR20180119663A (ko) 2018-11-02
BR112018067922B1 (pt) 2024-02-06
US20190071417A1 (en) 2019-03-07
CN109069514B (zh) 2023-12-29
BR112018067922A2 (pt) 2019-01-15
JP2019507769A (ja) 2019-03-22
JP2024028841A (ja) 2024-03-05
US20200039955A1 (en) 2020-02-06
CA3016068C (fr) 2024-02-27
ZA201805523B (en) 2019-11-27
KR102355154B1 (ko) 2022-01-26
EP4148053A1 (fr) 2023-03-15
US10981891B2 (en) 2021-04-20
AU2022204071B2 (en) 2023-11-23
BR122023025283A2 (pt) 2024-02-20

Similar Documents

Publication Publication Date Title
JP6997095B2 (ja) 抗菌性化合物およびその使用
JP6232429B2 (ja) ＲＯＲγＴ阻害剤としての３−シクロヘキセニルおよびシクロヘキシル置換インドールおよびインダゾール化合物およびそれらの使用
KR20100058530A (ko) 퀴놀론 유도체
US20090326018A1 (en) 2-Phenyl indene derivatives useful as estrogen receptor ligands
WO2017075341A1 (fr) Dérivés d&#39;imidazole fusionnés utilisés comme inhibiteurs d&#39;ido/tdo
US8895565B2 (en) Heterocyclic compound and use of the same
CZ281714B6 (cs) Piperidylmethylsubstituované deriváty chromanu
CA2689985C (fr) Derives de di(hetero)arylcyclohexane, leur preparation, leur utilisation et compositions pharmaceutiques les comprenant
JP2020500920A (ja) 置換ピラゾロアゼピン−４−オンおよびそれらのホスホジエステラーゼ阻害剤としての使用
TW201315469A (zh) 菸鹼乙醯膽鹼受體之新正向異位調節子
EA040011B1 (ru) Антибактериальные соединения и их применение
JP2016537398A (ja) 新規なチトクロムｐ４５０阻害剤及びこれらの使用方法
EA007074B1 (ru) 2-амино-6-(2,4,5-замещенный фенил)пиридины для применения в качестве ингибиторов синтазы оксида азота
JP2005060375A (ja) 含酸素複素環化合物
JPH10512552A (ja) ４，４−（二置換）シクロヘキサン−１−オン二量体および関連化合物
JP2002516601A (ja) ４，４−（二置換）シクロヘキサン−１−オン単量体および関連化合物
JP2005060376A (ja) ピペリジン誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181029

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20190522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210106

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210205

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210827

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211116

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211216

R150 Certificate of patent or registration of utility model

Ref document number: 6997095

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150